Pulse Biosciences to Showcase Novel nsPFA Technology at Canaccord Growth Conference

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

08/01/2025 - 07:00 AM

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation鈩� (nanosecond PFA or nsPFA鈩�) technology, today announced plans to present at the upcoming 45^th Canaccord Genuity Annual Growth Conference in Boston.

Pulse Biosciences鈥� Management is scheduled to present on Wednesday, August 13, 2025, at 11:00 am ET. A live and recorded webcast of the presentation will be available on the 鈥淓vents Calendar and Presentations鈥� page of the company鈥檚 investor website at .

About Pulse Biosciences庐

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company鈥檚 proprietary CellFX庐 nsPFA鈩� technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.